Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus

Virology

Volumn 352, Issue 2, 2006, Pages 390-399

  Oh, SangKon ^a,b   Stegman, Brian ^a   Pendleton, C David ^a   Ota, Martin O ^b   Pan, Chien Hsiung ^b   Griffin, Diane E ^b   Burke, Donald S ^b   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CD8; Cytotoxic T lymphocytes; Epitopes; Measles; Vaccines

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; HYBRID PROTEIN; ISOLEUCYLLEUCYLLEUCYLARGINYLLEUCYLASPARTYLVALYLGLYCYLTHREONINE; ISOLEUCYLLEUCYLPROLYLGLYCYLGLUTAMINYLASPARTYLLEUCYLGLUTAMINYLTYROSYLVALINE; LYSYLLEUCYLLEUCYLARGINYLTYROSYLTYROSYLTHREONYLGLUTAMYLISOLEUCINE; LYSYLLEUCYLMETHIONYLPROLYLASPARAGINYLISOLEUCYLTHREONYLLEUCYLLEUCINE; LYSYLLEUCYLTRYPTOPHYLCYSTEINYLARGINYLHISTIDYLPHENYLALANYLCYSTEINYLVALINE; LYSYLVALYLSERYLPROLYLTYROSYLLEUCYLPHENYLALANYLASPARAGINYLVALINE; MEASLES VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE; SERYLMETHIONYLTYROSYLARGINYLVALYLPHENYLALANYLGLUTAMYLVALYLGLYCYLVALINE; THREONYLLEUCYLLEUCYLASPARAGINYLASPARAGINYLCYSTEINYLTHREONYLARGINYLVALINE; TYROSYLVALYLLEUCYLLEUCYLALANYLVALYLLEUCYLPHENYLALANYLVALINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; CD8+ T LYMPHOCYTE; EXPERIMENTATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MEASLES; MEASLES VIRUS; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SYNTHESIS; TRANSGENIC MOUSE; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS RECOMBINANT; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; BINDING SITES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; HEMAGGLUTININS, VIRAL; HLA-A2 ANTIGEN; HUMANS; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, TRANSGENIC; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL FUSION PROTEINS;

MEASLES VIRUS; MUS MUSCULUS; VACCINIA VIRUS;

EID: 33747083153     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.04.040     Document Type: Article

References (60)

1. Ahlers J.D., Belyakov I.M., Matsui S., and Berzofsky J.A. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13 7 (2001) 897-908
2. Alkhatib G., and Briedis D.J. The predicted primary structure of the measles virus hemagglutinin. Virology 150 2 (1986) 479-490
3. Bautista-Lopez N., Ward B.J., Mills E., McCormick D., Martel N., and Ratnam S. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 18 14 (2000) 1393-1401
4. Buckland R., Gerald C., Barker R., and Wild T.F. Fusion glycoprotein of measles virus: nucleotide sequence of the gene and comparison with other paramyxoviruses. J. Gen. Virol. 68 Pt. 6 (1987) 1695-1703
5. Celluzzi C.M., Mayordomo J.I., Storkus W.J., Lotze M.T., and Falo Jr. L.D. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183 (1996) 283-287
6. Drillien R., Spehner D., Kirn A., Giraudon P., Buckland R., Wild F., and Lecocq J.-P. Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1252-1256
7. Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., Riviere Y., Danos O., Michel M.L., Kosmatopoulos K., and Lemonnier F.A. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur. J. Immunol. 31 10 (2001) 3064-3074
8. Gans H.A., Arvin A.M., Galinus J., Logan L., DeHovitz R., and Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280 6 (1998) 527-532
9. Gans H.A., Maldonado Y., Yasukawa L.L., Beeler J., Audet S., Rinki M.M., DeHovitz R., and Arvin A.M. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J. Immunol. 162 9 (1999) 5569-5575
10. Garenne M., Leroy O., Beau J.P., and Sene I. Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 338 8772 (1991) 903-907
11. Gerald C., Buckland R., Barker R., Freeman G., and Wild T.F. Measles virus haemagglutinin gene: cloning, complete nucleotide sequence analysis and expression in COS cells. J. Gen. Virol. 67 Pt. 12 (1986) 2695-2703
12. Griffin D.E., Ward B.J., and Esolen L.M. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J. Infect. Dis. 170 Suppl. 1 (1994) S24-S31
13. Gulukota K., and DeLisi C. HLA allele selection for designing peptide vaccines. Genet. Anal. 13 (1996) 81-86
14. Halsey N.A., Boulos R., Mode F., Andre J., Bowman L., Yaeger R.G., Toureau S., Rohde J., and Boulos C. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N. Engl. J. Med. 313 9 (1985) 544-549
15. Harrer E., Harrer T., Barbosa P., Feinberg M., Johnson R.P., Buchbinder S., and Walker B.D. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J. Infect. Dis. 173 (1996) 476-479
16. Herberts C.A., Stittelaar K.J., van der Heeft E., van Gaans-Van den Brink J., Poelen M.C., Roholl P.J., van Alphen L.J., Melief C.J., de Jong A.P., and van Els C.A. A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. J. Gen. Virol. 82 Pt. 9 (2001) 2131-2142
17. Hirayama M. Measles vaccines used in Japan. Rev. Infect. Dis. 5 3 (1983) 495-503
18. Holt E.A., Moulton L.H., Siberry G.K., and Halsey N.A. Differential mortality by measles vaccine titer and sex. J. Infect. Dis. 168 5 (1993) 1087-1096
19. Jaye A., Magnusen A.F., Sadiq A.D., Corrah T., and Whittle H.C. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children. J. Clin. Invest. 102 11 (1998) 1969-1977
20. Jaye A., Magnusen A.F., and Whittle H.C. Human leukocyte antigen class I- and class II-restricted cytotoxic T lymphocyte responses to measles antigens in immune adults. J. Infect. Dis. 177 5 (1998) 1282-1289
21. Komase K., Haga T., Yoshikawa Y., Sato T.A., and Yamanouchi K. Molecular analysis of structural protein genes of the Yamagata-1 strain of defective subacute sclerosing panencephalitis virus: III. Nucleotide sequence of the hemagglutinin gene. Virus Genes 4 2 (1990) 163-172
22. Komase K., Haga T., Yoshikawa Y., Sato T.A., and Yamanouchi K. Molecular analysis of structural protein genes of the Yamagata-1 strain of defective subacute sclerosing panencephalitis virus: IV. Nucleotide sequence of the fusion gene. Virus Genes 4 2 (1990) 173-181
23. Markowitz L.E., Chandler F.W., Roldan E.O., Saldana M.J., Roach K.C., Hutchins S.S., Preblud S.R., Mitchell C.D., and Scott G.B. Fatal measles pneumonia without rash in a child with AIDS. J. Infect. Dis. 158 2fs (1988) 480-483
24. Mori T., Sasaki K., Hashimoto H., and Makino S. Molecular cloning and complete nucleotide sequence of genomic RNA of the AIK-C strain of attenuated measles virus. Virus Genes 7 1 (1993) 67-81
25. + memory T cells in measles-seropositive individuals by in vitro peptide stimulation. Clin. Exp. Immunol. 102 1 (1995) 40-45
26. Nanan R., Rauch A., Kampgen E., Niewiesk S., and Kreth H.W. A novel sensitive approach for frequency analysis of measles virus-specific memory T-lymphocytes in healthy adults with a childhood history of natural measles. J. Gen. Virol. 81 Pt. 5 (2000) 1313-1319
27. Nijman H.W., Houbiers J.G.A., Vierboom M.P.M., van der Burg S.H., Drijfhout J.W., D'Amaro J., Kenemans P., Melief C.J.M., and Kast W.M. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23 (1993) 1215-1219
28. Oh S., Hodge J.W., Ahlers J.D., Burke D.S., Schlom J., and Berzofsky J.A. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J. Immunol. 170 (2003) 2523-2530
29. Oh S., Terabe M., Pendleton C.D., Bhattacharyy A., Bera T.K., Epel M., Reiter Y., Phillips J., Linehan W.M., Kasten-Sportes C., Pastan I., and Berzofsky J.A. Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res. 64 (2004) 2610-2618
30. Ovsyannikova I.G., Dhiman N., Jacobson R.M., Vierkant R.A., and Poland G.A. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin. Diagn. Lab. Immunol. 10 3 (2003) 411-416
31. Pan, C.-H., Valsamakis, A., Colella, T., Nair, N., Adams, R.J., Polack, F.P., Greer, C.E., Perri, S., Polo, J.M., and Griffin, D.E., in press. Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc. Natl. Acad. Sci.
32. Parker K.C., Bednarek M.A., and Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152 1 (1994) 163-175
33. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from B2 microglobulin (B2 m) HLA-A2.1 monochain transgenic H-2Db B2 m double knockout mice. J. Exp. Med. 185 (1997) 2043-2051
34. Permar S.R., Klumpp S.A., Mansfield K.G., Kim W.K., Gorgone D.A., Lifton M.A., Williams K.C., Schmitz J.E., Reimann K.A., Axthelm M.K., Polack F.P., Griffin D.E., and Letvin N.L. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J. Virol. 77 7 (2003) 4396-4400
35. Polack F.P., Lee S.H., Permar S., Manyara E., Nousari H.G., Jeng Y., Mustafa F., Valsamakis A., Adams R.J., Robinson H.L., and Griffin D.E. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med. 6 7 (2000) 776-781
36. Polo J.M., Gardner J.P., Ji Y., Belli B.A., Driver D.A., Sherrill S., Perri S., Liu M.A., and Dubensky Jr. T.W. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev. Biol. (Basel) 104 (2000) 181-185
37. Rammensee H.-G., Friede T., and Stevanovíc S. MHC ligands and peptide motifs: first listing. Immunogenetics 41 (1995) 178-228
38. Richardson C., Hull D., Greer P., Hasel K., Berkovich A., Englund G., Bellini W., Rima B., and Lazzarini R. The nucleotide sequence of the mRNA encoding the fusion protein of measles virus (Edmonston strain): a comparison of fusion proteins from several different paramyxoviruses. Virology 155 2 (1986) 508-523
39. Rose J.W., Bellini W.J., McFarlin D.E., and McFarland H.F. Human cellular immune response to measles virus polypeptides. J. Virol. 49 3 (1984) 988-991
40. Ruppert J., Sidney J., Celis E., Kubo R.T., Grey H.M., and Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74 (1993) 929-937
41. Schmid A., Spielhofer P., Cattaneo R., Baczko K., ter Meulen V., and Billeter M.A. Subacute sclerosing panencephalitis is typically characterized by alterations in the fusion protein cytoplasmic domain of the persisting measles virus. Virology 188 2 (1992) 910-915
42. Shirai M., Arichi T., Nishioka M., Nomura T., Ikeda K., Kawanishi K., Engelhard V.H., Feinstone S.M., and Berzofsky J.A. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154 (1995) 2733-2742
43. Siegrist C.A., Barrios C., Martinez X., Brandt C., Berney M., Cordova M., Kovarik J., and Lambert P.H. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur. J. Immunol. 28 12 (1998) 4138-4148
44. Song M.K., Vindurampulle C.J., Capozzo A.V., Ulmer J., Polo J.M., Pasetti M.F., Barry E.M., and Levine M.M. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J. Virol. 79 15 (2005) 9854-9861
45. Stittelaar K.J., Boes J., Kersten G.F., Spiekstra A., Mulder P.G., de Vries P., Roholl P.J., Dalsgaard K., van den Dobbelsteen G., van Alphen L., and Osterhaus A.D. In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine 18 23 (2000) 2482-2493
46. Stittelaar K.J., deSwart R.L., Vos H.W., vanAmerongen G., Sixt N., Wild T.F., and Osterhaus A.D. Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination. Vaccine 20 16 (2002) 2022-2026
47. Tamin A., Rota P.A., Wang Z.D., Heath J.L., Anderson L.J., and Bellini W.J. Antigenic analysis of current wild type and vaccine strains of measles virus. J. Infect. Dis. 170 4 (1994) 795-801
48. Tishon A., LaFace D.M., Lewicki H., van Binnendijk R.S., Osterhaus A., and Oldstone M.B. Transgenic mice expressing human HLA and CD8 molecules generate HLA-restricted measles virus cytotoxic T lymphocytes of the same specificity as humans with natural measles virus infection. Virology 275 2 (2000) 286-293
49. van Binnendijk R.S., Poelen M.C., Kuijpers K.C., Osterhaus A.D., and Uytdehaag F.G. The predominance of CD8+ T cells after infection with measles virus suggests a role for CD8+ class I MHC-restricted cytotoxic T lymphocytes (CTL) in recovery from measles. Clonal analyses of human CD8+ class I MHC-restricted CTL. J. Immunol. 144 6 (1990) 2394-2399
50. van Binnendijk R.S., van Baalen C.A., Poelen M.C.M., De Vries P., Boes J., Cerundolo V., Osterhaus A.D.M.E., and Uytdehaag F.G.C.M. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J. Exp. Med. 176 (1992) 119-128
51. van Binnendijk R.S., Poelen M.C., van Amerongen G., de Vries P., and Osterhaus A.D. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175 3 (1997) 524-532
52. van Els C.A., and Nanan R. T cell responses in acute measles. Viral. Immunol. 15 3 (2002) 435-450
53. van Els C.A., Herberts C.A., van der Heeft E., Poelen M.C., van Gaans-van den Brink J.A., van der Kooi A., Hoogerhout P., Jan ten Hove G., Meiring H.D., and de Jong A.P. A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur. J. Immunol. 30 4 (2000) 1172-1181
54. Vitiello A., Marchesini D., Furze J., Sherman L.A., and Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173 (1991) 1007-1015
55. Ward B.J., Boulianne N., Ratnam S., Guiot M.C., Couillard M., and De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J. Infect. Dis. 172 6 (1995) 1591-1595
56. Watts C., and Powis S. Pathways of antigen processing and presentation. Rev. Immunogenet. 1 1 (1999) 60-74
57. Wiertz E.J., Jones T.R., Sun L., Bogyo M., Geuze H.J., and Ploegh H.L. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84 5 (1996) 769-779
58. Wild T.F., Bernard A., Spehner D., and Drillien R. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. J. Gen. Virol. 73 Pt. 2 (1992) 359-367
59. Wild T.F., Bernard A., Spehner D., Villeval D., and Drillien R. Vaccination of mice against canine distemper virus-induced encephalitis with vaccinia virus recombinants encoding measles or canine distemper virus antigens. Vaccine 11 4 (1993) 438-444
60. Zhu Y., Rota P., Wyatt L., Tamin A., Rozenblatt S., Lerche N., Moss B., Bellini W., and McChesney M. Evaluation of recombinant vaccinia virus-measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276 1 (2000) 202-213